文献速递消化系统肿瘤

丹麦4163例胰腺癌患者初始治疗与生存:全国未选择真实世界登记研究

Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study.
PubMed 文献 · Eur J Cancer · 2020-02-29

该研究基于丹麦胰腺癌数据库2011至2016年4260例患者,排除97例后纳入4163例,分析切除、化疗或最佳支持治疗(BSC)与总生存(OS)的关系。结果显示切除组中位OS为21.9个月,化疗组中FOLFIRINOX方案最长(10.0个月)、吉西他滨最短(5.1个月),BSC组仅1.6个月;切除组OS与随机对照试验(RCT)相当,化疗组略短于RCT,反映未选择人群特征。

要点

  • 切除组中位OS为21.9个月,与RCT报告相当。
  • 化疗组中FOLFIRINOX中位OS为10.0个月,吉西他滨为5.1个月。
  • BSC组占41%,中位OS仅1.6个月,生存极差。

核心结论

  • 丹麦全国未选择胰腺癌人群中,切除组OS与RCT相当,化疗组略短于RCT,BSC组占比大且OS极差。

研究设计与样本

  • 基于丹麦胰腺癌数据库的全国性未选择真实世界登记研究,纳入2011年5月1日至2016年4月30日诊断的4163例胰腺癌患者。

主要发现

  • 718例(17%)接受切除,中位OS为21.9个月(范围20.0-24.2)。
  • 1746例(42%)接受化疗,FOLFIRINOX组中位OS最长,为10.0个月(9.2-11.0),吉西他滨组最短,为5.1个月(4.8-5.6)。
  • 1697例(41%)接受BSC,中位OS仅1.6个月(1.5-1.7)。

临床怎么用

  • 真实世界中胰腺癌切除患者生存与RCT相当,支持手术切除在未选择人群中的疗效。
  • 化疗患者生存略短于RCT,需考虑未选择人群的异质性。
  • BSC组占比高且生存极差,提示需关注该人群的治疗可及性与支持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nationwide register data on the effect of primary treatment on survival in an unselected population of patients with pancreatic cancer (PC) have not been reported before. The study aim was to investigate the overall survival (OS) related to initial treatment with resection, chemotherapy, or best supportive care (BSC) in all patients diagnosed with PC in Denmark from 2011 to 2016. METHODS: From 1 May 2011 to 30 April 2016, 4260 patients with PC were identified in the Danish Pancreatic Cancer Database. Ninety-seven patients (2%) were excluded, 56 because of treatment with preoperative chemotherapy, 39 because of incorrect registration of diagnosis or treatment, and 2 because of loss to follow-up; thus, 4163 patients were included. RESULTS: The 718 patients (17%) receiving resection had a median overall survival (mOS) of 21.9 months (range 20.0-24.2). In the chemotherapy group of 1746 patients (42%), those treated with FOLFIRINOX had the longest mOS of 10.0 months (9.2-11.0), whereas those treated with gemcitabine had the shortest mOS of 5.1 months (4.8-5.6). The 1697 patients (41%) receiving BSC had a mOS of only 1.6 months (1.5-1.7). CONCLUSIONS: The resected PC cohort had an OS comparable with that reported in randomised controlled trials (RCTs). The mOS of the chemotherapy-treated patients was slightly shorter compared with the results from RCTs and reflects the unselected population in this study. During the last decade, a larger fraction of patients received anticancer treatment, but the BSC group was still large and showed extremely poor OS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rasmussen LS, Fristrup CW, Jensen BV, et al. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Eur J Cancer. 2020. PMID: 32120275. doi:10.1016/j.ejca.2020.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。